Appendix Table C73. Clinical outcomes (outcomes part A), CCB versus placebo trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **All-cause Mortality****n/N (%)** | **Cardiovascular Mortality****n/N (%)** | **Myocardial Infarction,****Any, n/N (%)** | **Myocardial Infarction,****Fatal, n/N (%)** | **Myocardial infarction,****Nonfatal n/N (%)** | **Stroke, Any****n/N (%)** |
| **CCB** | **Placebo** | **CCB** | **Placebo** | **CCB** | **Placebo** | **CCB** | **Placebo** | **CCB** | **Placebo** | **CCB** | **Placebo** |
| Berl, 200360Lewis, 200140  | 83/567 (14.6) | 93/569 (16.3) | 37/567 (6.5) | 46/569 (8.1%) | 27/567 (4.8) | 46/569 (8.1) |  |  |  |  | 15/567 (2.6) | 26/569 (4.6) |
| Crepaldi, 199810 | 1/41 (2.4) | 0/49 | 1/41 (2.4) | 0/49 | 0/41 | 1/49 (2.0) |  |  |  |  |  |  |

CCB = calcium channel blocker